NCT06954584View on ClinicalTrials.gov

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

May 1, 2030

Study Completion Date

March 1, 2032

Conditions
Ovarian Cancer
Interventions
DRUG

Bevacizumab

Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 15 months

DRUG

Fluzoparib Monotherapy

150 mg orally bid (50 mg/capsule, 3 capsules/dose)

BEHAVIORAL

Dietary Intervention

Control carbohydrate intake in the daily diet

Trial Locations (2)

430000

RECRUITING

Tongji Hospital, Wuhan

Unknown

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Tongji Hospital

OTHER